Research output: Contribution to journal › Article › peer-review
Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats. / Ptukha, Maria; Fesenko, Zoia; Belskaya, Anastasia; Gromova, Arina; Pelevin, Arseniy; Kurzina, Natalia; Gainetdinov, Raul R; Volnova, Anna.
In: Biomolecules, Vol. 12, No. 10, 1484, 14.10.2022.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats
AU - Ptukha, Maria
AU - Fesenko, Zoia
AU - Belskaya, Anastasia
AU - Gromova, Arina
AU - Pelevin, Arseniy
AU - Kurzina, Natalia
AU - Gainetdinov, Raul R
AU - Volnova, Anna
N1 - Publisher Copyright: © 2022 by the authors.
PY - 2022/10/14
Y1 - 2022/10/14
N2 - Changes in dopaminergic and noradrenergic transmission are considered to be the underlying cause of attention deficit and hyperactivity disorder (ADHD). Atomoxetine (ATX) is a selective norepinephrine transporter (NET) inhibitor that is currently used for ADHD treatment. In this study, we aimed to evaluate the effect of atomoxetine on the behavior and brain activity of dopamine transporter knockout (DAT-KO) rats, which are characterized by an ADHD-like behavioral phenotype. Prepulse inhibition (PPI) was assessed in DAT-KO and wild type rats after saline and ATX injections, as well as behavioral parameters in the Hebb-Williams maze and power spectra and coherence of electrophysiological activity. DAT-KO rats demonstrated a pronounced behavioral and electrophysiological phenotype, characterized by hyperactivity, increased number of errors in the maze, repetitive behaviors and disrupted PPI, changes in cortical and striatal power spectra and interareal coherence. Atomoxetine significantly improved PPI and decreased repetitive behaviors in DAT-KO rats and influenced behavior of wild-type rats. ATX also led to significant changes in power spectra and coherence of DAT-KO and wild type rats. Assessment of noradrenergic modulation effects in DAT-KO provides insight into the intricate interplay of monoaminergic systems, although further research is still required to fully understand the complexity of this interaction.
AB - Changes in dopaminergic and noradrenergic transmission are considered to be the underlying cause of attention deficit and hyperactivity disorder (ADHD). Atomoxetine (ATX) is a selective norepinephrine transporter (NET) inhibitor that is currently used for ADHD treatment. In this study, we aimed to evaluate the effect of atomoxetine on the behavior and brain activity of dopamine transporter knockout (DAT-KO) rats, which are characterized by an ADHD-like behavioral phenotype. Prepulse inhibition (PPI) was assessed in DAT-KO and wild type rats after saline and ATX injections, as well as behavioral parameters in the Hebb-Williams maze and power spectra and coherence of electrophysiological activity. DAT-KO rats demonstrated a pronounced behavioral and electrophysiological phenotype, characterized by hyperactivity, increased number of errors in the maze, repetitive behaviors and disrupted PPI, changes in cortical and striatal power spectra and interareal coherence. Atomoxetine significantly improved PPI and decreased repetitive behaviors in DAT-KO rats and influenced behavior of wild-type rats. ATX also led to significant changes in power spectra and coherence of DAT-KO and wild type rats. Assessment of noradrenergic modulation effects in DAT-KO provides insight into the intricate interplay of monoaminergic systems, although further research is still required to fully understand the complexity of this interaction.
KW - ADHD
KW - atomoxetine
KW - coherence
KW - dopamine
KW - dopamine transporter knockout (DAT-KO) rats
KW - norepinephrine transporter (NET)
KW - power spectra
KW - prepulse inhibition
UR - http://www.scopus.com/inward/record.url?scp=85140450367&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/551a2c26-627b-3572-b471-3d37204458e1/
U2 - 10.3390/biom12101484
DO - 10.3390/biom12101484
M3 - Article
C2 - 36291693
VL - 12
JO - Biomolecules
JF - Biomolecules
SN - 2218-273X
IS - 10
M1 - 1484
ER -
ID: 99746938